You are here: Industry Insights > Market News > Lupin donates oxygen generation plants in Maharashtra, MP and Gujarat

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Lupin donates oxygen generation plants in Maharashtra, MP and Gujarat

expresspharmaJune 15, 2021

Tag: lupin , oxygen , Maharashtra

Favorites

Lupin, through its CSR arm, the Lupin Foundation, is donating five oxygen generation plants to assist the states of Maharashtra, Madhya Pradesh and Gujarat.

These five oxygen plants have a total capacity of 3840 cubic meters of oxygen per day.

The respective State governments will oversee the distribution of the oxygen produced at these plants to Government hospitals and COVID care centres.

The company informed that it is in discussions with other states to assist them in their fight against the pandemic through similar initiatives.

Previous:CSIR-CDRI, Lucknow sign license deal with Marc Labs to develop drug for treating heart attack, stroke

Next:Biophore applies for DCGI approval for emergency use of Aviptadil to treat COVID-19

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

PharmaSourcesMay 16, 2024

InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Lupin donates oxygen generation plants in Maharashtra, MP and Gujarat | Pharmasources.com

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.

Lupin donates oxygen generation plants in Maharashtra, MP and Gujarat

Related News

InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

You may like